Adoptive Immunotherapy in Postoperative Hepatocellular Carcinoma: a Systemic Review

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Aug 24

PMID 22916174

Citations 23

Authors

Feng Xie

Xinji Zhang

Hui Li

Tao Zheng

Feng Xu

Rongxi Shen

Long Yan

Jiamei Yang

Jia He

Affiliations

Soon will be listed here.

Abstract

Purpose: The effectiveness of immunotherapy for postoperative hepatocellular carcinoma patients is still controversial. To address this issue, we did a systemic review of the literatures and analyzed the data with emphasis on the recurrence and survival.

Methods: We searched six randomized controlled trials that included adoptive immunotherapy in the postoperative management of hepatocellular carcinoma and compared with non-immunotherapy postoperation. A meta-analysis was carried out to examine one- and 3-year recurrence and survival.

Results: The overall analysis revealed significantly reduced risk of 1-year recurrence in patients receiving adoptive immunotherapy (OR=0.35; 95% CI, 0.17 to 0.71; p=0.003), in that the risk of 3-year recurrence with a pooled OR estimated at 0.31 (95% CI 0.16 to 0.61; p=0.001). However, no statistically significant difference was observed for 3-year survival between groups with adoptive immunotherapy and without adjuvant treatment (OR=0.91; 95% CI, 0.45 to 1.84; P=0.792).

Conclusions: Adjuvant immunotherapy with cytokine induced killer cells or lymphokine activated killer cells may reduce recurrence in postoperative hepatocellular carcinoma patients, but may not improve survival.

Citing Articles

Progression-Free Survival of a Patient with Advanced Hepatocellular Carcinoma Treated with Adoptive Cell Therapy Using Natural Killer Cells: A Case Report.

Hong G, Xie S, Guo Z, Zhang D, Ge S, Zhang S Onco Targets Ther. 2022; 15:255-266.

PMID: 35313527 PMC: 8934175. DOI: 10.2147/OTT.S344707.

A Five-Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients.

Wang Z, Zhang N, Lv J, Ma C, Gu J, Du Y Biomed Res Int. 2020; 2020:4037639.

PMID: 33163533 PMC: 7604585. DOI: 10.1155/2020/4037639.

Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy.

Garofano F, Gonzalez-Carmona M, Skowasch D, Schmidt-Wolf R, Abramian A, Hauser S Int J Mol Sci. 2019; 20(17).

PMID: 31484350 PMC: 6747410. DOI: 10.3390/ijms20174307.

Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?.

Mahipal A, Tella S, Kommalapati A, Lim A, Kim R Cancers (Basel). 2019; 11(8).

PMID: 31366113 PMC: 6721326. DOI: 10.3390/cancers11081078.

Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review.

Hosseinzadeh F, Verdi J, Ai J, Hajighasemlou S, Seyhoun I, Parvizpour F Cancer Cell Int. 2018; 18:133.

PMID: 30214375 PMC: 6131874. DOI: 10.1186/s12935-018-0624-x.

References

Kanai T, Monden M, Takeda T, Gotoh M, Sakon M, Umeshita K . [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2]. Gan To Kagaku Ryoho. 1993; 20(11):1457-60. View

Tan A, Aucejo F, Kim R . Is there a role for adjuvant treatment after hepatic resection for hepatocellular carcinoma?. Oncology. 2010; 78(3-4):161-71. DOI: 10.1159/000315577. View

Haruta I, Yamauchi K, Aruga A, Komatsu T, Takasaki K, Hayashi N . Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy. J Immunother Emphasis Tumor Immunol. 1996; 19(3):218-23. DOI: 10.1097/00002371-199605000-00006. View

Lafreniere R, Rosenberg S . Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. 1985; 45(8):3735-41. View

Llovet J, Bruix J . Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003; 37(2):429-42. DOI: 10.1053/jhep.2003.50047. View

Kawata A, Une Y, Hosokawa M, Wakizaka Y, Namieno T, Uchino J . Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone. Am J Clin Oncol. 1995; 18(3):257-62. DOI: 10.1097/00000421-199506000-00014. View

Lygidakis N, Pothoulakis J, Konstantinidou A, Spanos H . Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Anticancer Res. 1995; 15(2):543-50. View

Grimm E, Mazumder A, Zhang H, Rosenberg S . Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982; 155(6):1823-41. PMC: 2186695. DOI: 10.1084/jem.155.6.1823. View

Schmidt-Wolf I, Negrin R, Kiem H, Blume K, Weissman I . Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991; 174(1):139-49. PMC: 2118875. DOI: 10.1084/jem.174.1.139. View

10.

Kubo S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Yamamoto T . Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer. 2000; 88(5):1016-24. DOI: 10.1002/(sici)1097-0142(20000301)88:5<1016::aid-cncr10>3.0.co;2-v. View

11.

Xie L, Pang R, Jin Y, Xiang S, Li H . Effects of hepatic artery chemotherapeutic embolization combined with perfusing LAK cells into hepatic artery after radical operation of liver cancer. Zhonghua Gan Zang Bing Za Zhi. 2000; 8(3):142-3. View

12.

Hui D, Qiang L, Jian W, Ti Z, Da-Lu K . A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis. 2008; 41(1):36-41. DOI: 10.1016/j.dld.2008.04.007. View

13.

de Visser K, Coussens L . The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol. 2006; 13:118-137. DOI: 10.1159/000092969. View

14.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

15.

Linn Y, Hui K . Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol. 2010; 2010:435745. PMC: 2847766. DOI: 10.1155/2010/435745. View

16.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

17.

Chang H, Hsieh K, Yeh C, Tu Y, Sheu F . Oral administration of an Enoki mushroom protein FVE activates innate and adaptive immunity and induces anti-tumor activity against murine hepatocellular carcinoma. Int Immunopharmacol. 2009; 10(2):239-46. DOI: 10.1016/j.intimp.2009.10.017. View

18.

Shi M, Zhang B, Tang Z, Lei Z, Wang H, Feng Y . Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol. 2004; 10(8):1146-51. PMC: 4656350. DOI: 10.3748/wjg.v10.i8.1146. View

19.

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

20.

Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J . Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000; 356(9232):802-7. DOI: 10.1016/S0140-6736(00)02654-4. View